JMP Securities analyst Jason Butler reiterated a Buy rating on ACADIA Pharmaceuticals (ACAD – Research Report) today and set a price target of $37.00.
Jason Butler has given his Buy rating due to a combination of factors that highlight ACADIA Pharmaceuticals’ promising growth trajectory. The company has demonstrated a clear commercial strategy that is expected to drive significant growth in 2025, particularly as their pipeline becomes more defined. ACADIA’s flagship product, NUPLAZID, continues to perform strongly, with expectations for meaningful growth over the coming years, supported by effective marketing campaigns and educational efforts.
Additionally, the company has a stable base for its product DAYBUE, with anticipated growth in the latter half of 2025. Despite a slight reduction in DAYBUE sales projections, the overall outlook remains positive due to the company’s robust cash flow and strategic investments in pipeline programs. These factors, combined with the potential for long-term value from ongoing and future projects, underpin Butler’s confidence in ACADIA’s ability to outperform the market.
In another report released yesterday, TD Cowen also maintained a Buy rating on the stock with a $35.00 price target.
Questions or Comments about the article? Write to editor@tipranks.com